Business Context and Reporting Period
This Form 8-K was filed by Rosewind Corporation (noted as AYTU BIOPHARMA, INC in metadata) on May 20, 2015. The report details the entry into a Material Definitive Agreement and the completion of an asset acquisition.
Key Financial Metrics and Transaction Details
The filing discloses a specific asset purchase transaction rather than standard periodic financial results (revenue, profit, or cash flow).
- Acquisition Target: ProstaScint Business (including intellectual property, contracts, approvals, inventory, and work in progress) from Jazz Pharmaceuticals, Inc.
- Closing Payment: $1.0 million paid at closing.
- Inventory Payment: $500,000 payable within five days of transfer.
- FDA Fees Payment: $226,523 payable on September 30, 2015.
- Contingent Consideration: 8% royalty on net sales made after October 31, 2017, capped at a maximum aggregate payment of $2.5 million.
- Liabilities Assumed: Certain liabilities related to product approvals and the sale/marketing of ProstaScint.
Material Changes
The primary material change is the expansion of the company's portfolio through the acquisition of the ProstaScint Business. The filing does not provide comparative financial data (e.g., year-over-year revenue or profit changes) as this is a current event report.
Outlook, Risks, and Contingencies
- Non-Compete: The Seller (Jazz Pharmaceuticals) agreed to a one-year non-compete clause, prohibiting direct competition or acquiring businesses where more than 15% of revenue is generated by competing products.
- Indemnification: The agreement includes customary indemnification provisions for breaches of representations, warranties, or covenants, as well as liabilities arising from the business prior to closing (assumed by Rosewind) and after closing (assumed by Seller).
- Financial Reporting: The company is preparing required financial statements for the ProstaScint Business, with a filing deadline of July 30, 2015.
Investor Verification Checklist
- Verify the exact total consideration paid, including the timing of the $500,000 inventory payment and the $226,523 FDA fee payment.
- Review the full Asset Purchase Agreement (Exhibit 10.14) for specific details on assumed liabilities and indemnification limitations.
- Monitor the upcoming filing of financial statements for the ProstaScint Business due by July 30, 2015.
- Confirm the definition of "net sales" used for the 8% royalty calculation to assess the potential $2.5 million cap exposure.